Genetics study UK

A clinical trial is underway for a potential new treatment for type 1 diabetes that could eventually mean patients are able to reduce insulin treatment from several times a day to once or twice a week. The new treatment is a direct result of research to understand the genetics of the disease.

Type 1 diabetes is the most common severe chronic autoimmune disease worldwide, and the incidence of the disease is rising rapidly. It causes the immune system to mistake cells in the pancreas for harmful cells and attack them. When these cells are damaged the pancreas is unable to produce insulin, which plays an essential part in transferring glucose out of the bloodstream and into cells to be converted into energy.

The management of type 1 diabetes usually involves measuring the amount of glucose in the blood and injecting artificial insulin to make up for the insulin the pancreas is not producing.

Type 1 diabetes is known to be a genetically complex disease - there is no single gene that causes the disease, but rather dozens of genes that increase the risk of developing it. However, genetic studies have identified variants of one particular gene - known as interleukin-2, or IL2 - that seems to have a prominent role. IL-2 is important in helping regulate the immune system.

Now, for the first time, researchers at Addenbrooke's Hospital and the Wellcome Trust-funded Cambridge Institute for Medical Research (CIMR) at the University of Cambridge are investigating whether interleukin-2 in the form of a drug called aldesleukin (Proleukin) could be used to halt the damage to the pancreas in people with newly diagnosed type 1 diabetes and, if so, what dose of the drug is required for the best results.

Professor John Todd FRS from the JDRF/Wellcome Trust Diabetes and Inflammation Laboratory, University of Cambridge, says: "Studying the genetics of type 1 diabetes has proved essential to help us understand what is happening in the disease at a cellular and molecular level. This type of research takes time, but we are now beginning to test its true potential for improving the lives of patients in our innovative translational medicine programme."

The clinical trial is being led by Dr Frank Waldron-Lynch from the University of Cambridge and is coordinated by the Cambridge Clinical Trials Unit at Addenbrooke’s Hospital. Dr Waldron-Lynch adds: "Type 1 diabetes is a potentially very serious disease that requires lifelong treatment and regular insulin injections throughout the day. Our aim is to use aldesleukin to rebalance the immune system so that patients can significantly reduce the number of insulin injections needed to just once or twice a week by slowing the progression of the disease."

The first two participants have been enrolled onto the trial and have received treatment. At the moment, the trial is to help gauge the necessary dose in adults, beginning with very low doses; ultimately, the researchers hope to be able to use this treatment in children.

Dr Waldron-Lynch says that so far the results have been very positive, even on a very low dose, with no detectable side-effects. However, they are looking to recruit more participants to the 'adaptive study of IL-2 dose on regulatory T cells in type 1 diabetes' (DILT1D) to help them determine with confidence whether the drug is effective and at what dose.

The trial is being funded by the Wellcome Trust and JDRF, the type 1 diabetes charity, combined with funding from the National Institute for Health Research, a UK government body that coordinates and funds research for the NHS.